Recombinant human C1 esterase inhibitor as short-term prophylaxis in patients with hereditary angioedema
2020
Abstract
Hereditary angioedema (HAE), an inherited deficiency of functional C1 esterase inhibitor (C1-INH), is characterized by recurrent episodes of disabling and often painful swelling in subcutaneous and/or submucosal tissues.1 HAE attacks are generally unpredictable, but triggers for an attack can include having a dental or medical procedure (eg, surgery), other trauma, or stress. A preemptive management plan for patients undergoing these types of situations may reduce the risk of HAE attacks.2 Recommendations include administration of short-term prophylaxis in patients with HAE before invasive medical procedures, especially those involving the upper airways or digestive tract, with C1-INH concentrate typically the medication of choice.